TD Cowen is Bullish on Adaptive Biotechnologies Corporation (ADPT)

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is among the Most Volatile Stocks.

On February 6, 2026, TD Cowen upgraded Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s price target to $21 from $20 while keeping a Buy rating, citing a Q4 beat and an improved outlook. TD Cowen said that community adoption, new indications, pharma guidelines, EMR integrations, and a shift to blood-based testing were major driving factors.

On February 6, 2026, BTIG maintained a Buy rating on Adaptive Biotechnologies Corporation (NASDAQ:ADPT) and increased its price target from $21 to $22, following Q4 earnings. BTIG describes the company as a leading growth story in specialty labs.

On February 6, 2026, JPMorgan boosted Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s price objective from $20 to $21 while retaining an Overweight rating, citing the Q4 report as strong. The corporation anticipates FY26 MRD business revenue of $255 million to $265 million, with total operating expenses, including cost of revenue, ranging from $350 million to $360 million.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) develops an immune medicine platform. The company provides immunoSEQ, clonoSEQ, cellular treatment, and vaccinations.

While we acknowledge the potential of ADPT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 20 Best Performing Stocks in 2025 and 12 Best Food Stocks to Buy in 2026.

Disclosure: None.